Journal Article (Editorial)

DKFZ-2022-03208

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Editorial: Immunotherapy for NSCLC with oncogenic driver variants.

Du, Y. ; Chu, Q. ; Lou, Y. ; He, Y. ; Hu, H. ; Hu, Q.DKFZ* ; Huang, M.

2022
Frontiers Media Lausanne

This record in other databases:

Please use a persistent id in citations: doi:10.3389/fonc.2022.1095947

Keyword(s): immune checkpoint inhibitors ; lung cancer ; oncogenic driver variants ; targeted therapy resistance ; tumor immune microenvironment

---

Contributing Institute(s):

1. F100 Pathologie infektionsbedingter Tumoren (F100)

Research Program(s):

1. 316 - Infektionen, Entzündung und Krebs (POF4-316) (POF4-316)

Appears in the scientific report 2022

---

Database coverage:
; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---